The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Subscribe To Our Newsletter & Stay Updated
